Radioisotope manufacturer International Isotopes has inked an agreement in principle with Idaho State University (ISU) to jointly develop processes to produce copper-67, an isotope with potential for treating non-Hodgkin's lymphoma and bladder, colorectal, and ovarian cancers.
Under terms of the agreement, ISU will produce the raw isotope at its Idaho Accelerator Center. International Isotopes will then transfer the material to its facility, where it will be processed and packaged in its final form, the company said.
ISU will also provide its chemical processing knowledge, while International Isotopes will make an in-kind contribution of equipment for isotope processing, technical support for packaging and shipping, and supporting safety staff. ISU and International Isotopes expect to execute definitive agreements within the coming weeks and plan to begin work later this month.
